AVTR vs. RDY: Avantor vs. Dr. Reddy's Laboratories Stock Comparison
How do Avantor (AVTR) and Dr. Reddy's Laboratories (RDY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and Dr. Reddy's Laboratories (RDY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while RDY is classified in Pharmaceuticals.
Avantor (AVTR) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | AVTR | RDY |
|---|---|---|
| Name | Avantor, Inc. | Dr. Reddy's Laboratories Ltd. ADR |
| Country/Region | United States | India |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 10.48 billion USD | 12.43 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | May 17, 2019 | April 11, 2001 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | RDY |
|---|---|---|
| Total Return (1Y) | 36.41% | 12.49% |
| Total Return (3Y, Annualized) | -5.02% | 5.76% |
| Total Return (5Y, Annualized) | -16.62% | 4.06% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | RDY |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 27.06% |
| Beta (5Y) | 0.94 | 0.30 |
| Max Drawdown (5Y) | -82.42% | -32.01% |
| Avg. Volume (3M) | 8.56M | 2.89M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | RDY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 0.30 |
| Sortino Ratio (1Y) | 1.17 | 0.43 |
Profitability
ROE (TTM)
Dr. Reddy's Laboratories (RDY) at 7.34% sits in the top ROE quartile, while Avantor (AVTR) at 5.91% is closer to the peer norm — stronger capital efficiency for RDY.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RDY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.34%
- Max
- 109.18%
- RDY
- 7.34%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both Avantor (AVTR) at 5.08% and Dr. Reddy's Laboratories (RDY) at 8.49% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RDY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.49%
- Max
- 18.05%
- RDY
- 8.49%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Avantor (AVTR) at 8.19% and Dr. Reddy's Laboratories (RDY) at 14.73% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RDY
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.73%
- Max
- 83.12%
- Q3
- 14.77%
- RDY
- 14.73%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | RDY |
|---|---|---|
| ROE (TTM) | 5.91% | 7.34% |
| ROA (TTM) | 2.83% | 3.37% |
| Net Margin (TTM) | 5.08% | 8.49% |
| Operating Margin (TTM) | 8.19% | 14.73% |
| Gross Margin (TTM) | 31.59% | 49.49% |
Growth
Revenue Growth
Dr. Reddy's Laboratories (RDY) at 3.19% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Dr. Reddy's Laboratories (RDY) at -24.14% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | AVTR | RDY |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | 3.19% |
| Revenue Growth (3Y CAGR) | -4.46% | 10.96% |
| EPS Growth (YoY) | -175.00% | -24.14% |
| EPS Growth (3Y CAGR) | -- | -1.72% |
Financial Strength
Current Ratio (MRQ)
Both Avantor (AVTR) at 1.89 and Dr. Reddy's Laboratories (RDY) at 1.93 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
RDY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.93
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- RDY
- 1.93
- Min
- 0.10
Debt / Equity (MRQ)
Both Avantor (AVTR) at 0.63 and Dr. Reddy's Laboratories (RDY) at 0.19 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RDY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19
- Max
- 1.42
- Q3
- 0.65
- RDY
- 0.19
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | RDY |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 1.93 |
| Debt / Equity (MRQ) | 0.63 | 0.19 |
| Net Debt / EBITDA | 3.40 | -0.08 |
Dividends
Dividend Yield (TTM)
Avantor (AVTR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a yield of 55.06%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RDY
Pharmaceuticals, Biotechnology & Life Sciences industry group
55.06%
- RDY
- 55.06%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Avantor (AVTR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a payout of 22.72%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RDY
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.72%
- RDY
- 22.72%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | RDY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 55.06% |
| Dividend Payout Ratio (TTM) | 0.00% | 22.72% |
Valuation
P/E Ratio (TTM)
Both Avantor (AVTR) at 30.94 and Dr. Reddy's Laboratories (RDY) at 41.42 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
RDY
Pharmaceuticals, Biotechnology & Life Sciences industry group
41.42
- Max
- 85.34
- Q3
- 43.46
- RDY
- 41.42
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Both Avantor (AVTR) at 1.58 and Dr. Reddy's Laboratories (RDY) at 0.04 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
RDY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- RDY
- 0.04
- Min
- 0.01
P/B Ratio (MRQ)
Avantor (AVTR) at 1.80 sits near its industry’s typical P/B ratio, while Dr. Reddy's Laboratories (RDY) at 18.16 prices above its benchmark range — RDY looks rich relative to book.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
RDY
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.16
- RDY
- 18.16
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | RDY |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | 41.42 |
| P/S Ratio (TTM) | 1.58 | 0.04 |
| P/B Ratio (MRQ) | 1.80 | 18.16 |
| Free Cash Flow Yield (TTM) | 4.21% | -53.03% |